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Aim. Nonsteroidal anti-inflammatory drugs or opioids are commonly used to control surgical pain following veterinary and clinical
procedures. This study evaluated the efficacy of postoperative ketorolac or buprenorphine following abdominal surgery. Main
Methods. Mean arterial pressure (MAP), heart rate, animal activity, corticosterone levels, and a nociceptive sensitivity assay were
used to evaluate 18 adult male Sprague-Dawley rats which underwent aortic artery occlusion for implantation of a radiotelemetry
device. The animals were treated postoperatively with intraperitoneal injections of vehicle, ketorolac (10mg/kg), or buprenorphine
(0.06mg/kg) every 8 hours for 3 days.Key Findings.There were no consistent significant changes in any of the telemetry parameters
after treatment with ketorolac compared with no saline treatment with the exception of increasedMAP in the buprenorphine group
during the first 48 hours when compared with other treatment groups.There was a sustained increase in fecal corticosterone levels
from baseline on days 2–7 with buprenorphine compared with vehicle- or ketorolac-treated animals. All treatment conditions
displayed reduced paw withdrawal thresholds (PWTs) from day 1 to day 21 following surgery. Compared with the vehicle treatment
group, buprenorphine-treated animals exhibited significantly lower PWT levels from day 4 to 14 days. Significance. Given the
prolonged increase in fecal corticosterone levels and pronounced changes in tactile hyperalgesia behavior in rodents subjected to
buprenorphine treatment, these data suggest that ketorolac may be superior to buprenorphine for the treatment of postprocedure
pain behavior in rodents.
1. Introduction
The effective relief of postoperative pain is of paramount
importance to the human or animal patient and ineffective
pain relief following surgery may associate with the onset of
chronic pain syndromes. More importantly for basic inves-
tigators, poorly controlled persisting pain following survival
surgeriesmay both adversely impact the welfare of laboratory
animals and confound the interpretation of experimental
results.
The goal of proper postoperative pain management is
to minimize pain and discomfort without producing unac-
ceptable side effects. Nonsteroidal anti-inflammatory drugs
(NSAIDs) such as ketorolac and/or opiate analgesics are
traditionally used to control pain under these circumstances.
Ketorolac is a potent analgesic commonly used for short-term
management of postoperative pain [1]. Ketorolac, like other
NSAIDs, has both analgesic and anti-inflammatory actions,
with its mechanism of action predominantly through inhibi-
tion of the enzyme cyclooxygenase, inhibiting prostaglandin
synthesis [2]. Side effects of chronic administration of
NSAIDs include ulceration of the GI tract, impairment of
platelet aggregation, nephrotoxicity, bone healing impair-
ment, and hepatotoxicity. However, these problematic side
effects are rarely seen with short-term administration [3, 4].
Severe pain arising from deep or visceral structures
typically requires the use of opiates. The effective duration
of many opiates is short in rodents, making several of
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these compounds (morphine, meperidine, and pentazocine)
impractical. A widely used opiate in rodents and companion
animals is buprenorphine, a mixed agonist and antagonist
with persisting clinical effects (8–12 hours) [5]. However,
buprenorphine shares many side effects with other opiates.
The most common side effects in rodents include consti-
pation and drowsiness. Larger doses produce respiratory
depression and hypotension.
Assessing the level of pain in rodents recovering from
surgery is controversial. General indicators of pain include
decreased water and food intake, loss of weight, decreased
home cage activity, and altered social interactions with others
in the cage [6–8]. Other indicators of localized discom-
fort include spontaneous biting of affected limbs, flinching,
guarding, licking, lifting, and shaking [9]. Additional meth-
ods for assessing pain in rodents include the measurement
of involuntary movements made in response to a stimulus.
For example, the nociceptive withdrawal reflex to a high-
intensity stimulus is thought to reflect acute pain while the
presence of spontaneous or evoked behavioral responses in
animalsmay be indicative of a persistent pain. It has also been
suggested that changes in heart rate, respiratory rate, and
blood pressure and changes in the hypothalamus-pituitary-
adrenal (HPA) axismay provide information on surgical pain
states in rodents [10–12].
The current experiments were conducted using rats sub-
jected to abdominal surgery. The telemetry devices recorded
the effects of postoperative treatment with vehicle, ketorolac,
or buprenorphine on blood pressure, heart rate, and home
cage activity. We also tested the hypothalamus-pituitary-
adrenal (HPA) axis function as measured by fecal corticos-
terone levels and determined the presence of tactile hyper-
algesia as assayed with von Frey-type probes in conscious,
unrestrained rodents. A major result of this rodent study
indicates that ketorolac during the postoperative period
provides superior analgesic control to buprenorphine over a
period of 21 days.
2. Methods
2.1. Animals. Pathogen-free, adult male Sprague-Dawley rats
(250–300 g; Harlan Laboratories, Madison, WI) were housed
in constant temperature (23 ± 3∘C) rooms with standard
rodent chow and water available ad libitum. The animals
were subjected to consistent cycles of light and darkness (12 h
light : 12 h dark cycle, lights on at 07:00 h and off at 19:00 h).
Experiments were performed during the light cycle. All ani-
mals were subjected to behavioral assays prior to treatment
and randomly assigned to one of the three experimental
treatment groups (vehicle 𝑛 = 7, ketorolac 𝑛 = 8, and
buprenorphine 𝑛 = 8). These experiments were approved
by the Institutional Animal Care and Use Committee of
Loyola University, Chicago. All procedures were conducted
in accordance with the Guide for Care and Use of Laboratory
Animals published by the National Institutes of Health and
the ethical guidelines of the International Association for the
Study of Pain. All behavioral testing of the treatment groups
took place within the Loyola University Animal Facility.
2.2. Telemetric Studies for Analysis of Blood Pressure, Heart
Rate, and Activity in Conscious Unrestrained Rats. While
under surgical levels of isoflurane anesthesia (as defined by
lack of purposeful response to surgical incision), biotelemetry
blood pressure/activity transmitters (Model TA11PA-C40;
Data Sciences, St. Paul) were implanted in the abdominal
cavity of the rats. The nonflushable catheters for measuring
arterial pressure were inserted into the descending aorta just
below the renal artery following the permanent occlusion
of the abdominal aorta 10mm below renal artery bifurca-
tion. Signals arising from each transmitter were captured
by a telemetry receiver interfaced with a microcomputer
for data acquisition and analysis. All surgeries were per-
formed between 8 AM and noon, and values for heart
rate, blood pressure, and activity were recorded continually
at a 10-minute interval beginning at 2 PM on the day of
implantation. Data were used to examine average hourly
values for heart rate, mean arterial pressure (MAP), and
activity beginning after recovery from surgical anesthesia and
demonstration of normal conscious behaviors. The activity
count is measured as a change in the signal strength from
the transmitter/telemetry device and the receiver, which can
occur from a change in the distance or orientation. This
count does not represent a measure of distance traveled.
Therefore, activity is presented as a relativemeasure of animal
movement around the cage.
2.3. Analgesics. Drugs utilized in this study represent the rat
formulary doses suggested byNIHOffice of Animal Care and
Use (http://oacu.od.nih.gov/arac/documents/Pain and Dis-
tress.pdf) and were administered immediately after comple-
tion of surgery and every 8 hours thereafter for a total of 9
doses (ketorolac, 10mg/kg, intraperitoneal; buprenorphine,
0.06mg/kg, intraperitoneal; or vehicle/saline, intraperi-
toneal). The last dose was administered 64 hours after
completion of surgery.
2.4. Fecal Corticosterone. All animals were housed individu-
ally in cages before and after implantation of the telemetry
devices. Fecal pellets were collected on the morning before
the implantation surgery and each morning for days 1–
3 and then every other day for 13 days; the pellets were
frozen at −20∘F until assayed. On the day before the assay,
each pellet sample was ground down to a powder and then
weighed for an amount between 0.45 and 0.55 grams and
placed into individual sample tubes. Next, 5mL of ethanol
was added to each tube; tubes were rocked overnight to
extract corticosterone. Following centrifugation at 1500 rpm
for 15 minutes, the corticosterone concentration in the super-
natant was determined utilizing a corticosterone enzyme
immunoassay kit (Assay Designs, Ann Arbor, MI) according
to themanufacturer’s instructions. Valueswere reported as ng
corticosterone/gm fecal pellet.
2.5. Foot Withdrawal to Punctate Mechanical Indentation.
Foot withdrawal in response tomechanical indentation of the
plantar surface of each hind paw was assessed with von Frey-
type filaments. Mechanical stimuli were applied with seven
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filaments, each differing in the bending force delivered (10,
20, 40, 60, 80, 100, and 120mN). Each filament was fitted
with a flat tip and a fixed diameter of 0.2mm [13–16]. The
force equivalence ofmN to grams is as follows: 100mN equals
10.197 g.
Rats were placed on a metal mesh floor and covered with
a transparent plastic dome. Typically, the animals rest quietly
in this situation after an initial period of exploration. Animals
were habituated to this testing apparatus, two days prior to the
behavioral assays. Following acclimation, each filament was
applied to six locations spaced across the nerve distribution
of hind paw glabrous skin.The filaments were tested in order
of ascending force, with each filament delivered in sequence
from the 1st to the 6th location alternating from one hind paw
to the other. The duration of each stimulus was 1 second and
the interstimulus interval was 10–15 seconds. A cutoff value
of 120mN was used; animals that did not respond at 120mN
were assigned that value [15, 16]. In each behavioral testing
sequence, the operator was blinded to the animal treatment
condition and the blinding codes were not revealed until the
completion of the data collection.
The incidence of paw withdrawal was expressed as a
percentage of the six applications of each filament as a
function of force. A Hill equation (coefficient of 1) was
fitted to the function (Origin version 6.0, Microcal Software,
Northampton, MA) relating the percentage of indentations
eliciting a withdrawal to the force of indentation. From this
equation, the paw withdrawal threshold (PWT) force was
obtained and defined as the force corresponding to a 50%
withdrawal. At least a −20mN difference from the baseline
PWT in a given animal is representative of mechanical
hypernociception [15, 16]. The experimenter was blinded to
both the injury condition of the animal and the drugs utilized
in all behavioral trials.
2.6. Statistics. Biotelemetric activity and fecal cortisol values
were evaluated using ANOVA with post hoc analysis (Sig-
maStat, SPSS, Inc.). The criterion for statistical significance
was 𝑝 < 0.05. Values are presented as mean ± SEM.
Statistical analysis of changes in mechanical paw withdrawal
thresholds was carried out using repeated measures two-
way ANOVA followed by Bonferroni’s post hoc test. The
behavioral criterion for statistical significance was 𝑝 < 0.05.
3. Results
3.1. Heart Rate. Opiates have little effect on the myocardium
during surgical procedures; however postoperative monitor-
ing of heart rate indicates that there was a trend towards
a lower heart rate in the buprenorphine-treated rodent as
compared to the saline and ketorolac groups during the
first 4 days after surgery (Figure 1) though these differences
were not statistically significant. Heart rate was significantly
greater in the buprenorphine group as compared to the other
two groups at most intervals from postoperative hours 140
through 146 (76 hours after the last dose of buprenorphine).
No other time- or group-related differences were observed in
heart rate.
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Figure 1: Heart rate is not altered by surgical procedure in
combination with vehicle, ketorolac, or buprenorphine. Heart rate
in saline-treated (𝑛 = 7, open circles), ketorolac-treated (𝑛 = 8,
blue closed squares), and buprenorphine-treated (𝑛 = 8, red closed
circles) rats after surgery for implantation of biotelemetry devices.
Treatmentwith analgesic or salinewas continued for three days, with
the last dose being given 64 hours after surgery. Time 0 represents 2
PM on the day of surgery, a time at which all animals had recovered
from anesthesia.
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Figure 2:Mean arterial pressure is not altered by surgical procedure
in combination with vehicle, ketorolac, or buprenorphine. Mean
arterial pressure in saline-treated (𝑛 = 7, open circles), ketorolac-
treated (𝑛 = 8, blue closed squares), and buprenorphine-treated
(𝑛 = 8, red closed circles) rats after surgery for implantation
of biotelemetry devices. Treatment with analgesic or saline was
continued for three days, with the last dose being given 64 hours
after surgery. Time 0 represents 2 PM on the day of surgery, a time
at which all animals had recovered from anesthesia.
3.2. Mean Arterial Pressure (MAP). Normal values for aver-
age blood pressure during a cardiac cycle during surgical
procedures vary with species and the cardiovascular action
of opiates may further alter normal physiologic values. As
shown in Figure 2, there were no differences in MAP
between saline-treated and ketorolac-treated rats at any time
after implantation of the telemetry devices. Values for MAP
in buprenorphine-treated animals were significantly greater
than those in the other two groups during the first two days
after surgery and again on days 5 through 7; values in the
buprenorphine groupwere also significantly greater at several
sample periods between postoperative hours 11 and 30 and
postoperative hours 123 and 160.
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Figure 3: Home cage activity is not altered by surgical procedure
in combination with vehicle, ketorolac, or buprenorphine. Activity
in vehicle-treated (𝑛 = 7, open circles), ketorolac-treated (𝑛 = 8,
blue closed squares), and buprenorphine-treated (𝑛 = 8, red closed
circles) rats after surgery for implantation of biotelemetry devices.
Treatmentwith analgesic or salinewas continued for three days, with
the last dose being given 64 hours after surgery. Time 0 represents 2
PM on the day of surgery, a time at which all animals had recovered
from anesthesia.
3.3. Home Cage Activity. Uninterrupted recordings of home
cage activity were obtained in all three treatment conditions.
As shown in Figure 3, animal movement activity did not
differ among the three treatment groups at any time after
abdominal surgery.
3.4. Fecal Corticosterone. Corticosterone is a stress hormone
that is regulated through activation of the HPA axis. Stress
and injury have been shown to lead to increased circulating
levels of corticosterone [12, 17]. Fecal samples represent
effective and noninvasive means to measure changes in
corticosterone [18–22]. Therefore, to determine the degree
to which abdominal surgery in combination with saline,
ketorolac, or buprenorphine contributes to a stress response,
we measured fecal corticosterone for 13 days. As shown
in Figure 4, there were no significant differences in fecal
corticosterone levels among the three groups of animals prior
to surgery (day 0). Values in each group were increased above
control levels on the first day after surgery (day 1). In the
saline and ketorolac groups, values reached their greatest
levels on day 1 and returned to near control values by day 3
after surgery, remaining unchanged during the remainder of
the 13-day period. In contrast, values in the buprenorphine
group continued to increase on day 2 after surgery and
recovered gradually back to control levels by day 9. Values
in the buprenorphine group were significantly greater than
those of the other two groups on days 2, 5, and 7.
3.5. Injury-Induced Alterations in Tactile Hyperalgesia. The
effect of abdominal surgery in combination with vehicle,
ketorolac, and buprenorphine on reflexive withdrawal to
mechanical stimulus was assessed using von Frey filaments.
Separate groups of rats were used over a course of 21 days.
Prior to surgery, the average PWT response to the von
Frey test was 75 ± 3mN (Figure 5). From day 1 to day
21, all treatment groups PWTs were significantly different
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Figure 4: Fecal corticosterone levels in vehicle-treated (𝑛 = 7,
closed circles), ketorolac-treated (𝑛 = 8, closed squares), and
buprenorphine-treated (𝑛 = 8, closed diamonds) rats before and
after surgery for implantation of biotelemetry devices. Treatment
with analgesic or saline began immediately after surgery and was
continued for 3 days. Fecal pellets were collected on days 2, 3, 5,
7, 9, 11, and 13 between 8 AM and noon. Significantly different
values were collected for only the buprenorphine-treated group
when compared with saline- and ketorolac-treated animals; ∗𝑝 <
0.05.
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Figure 5: Mean mN change in paw withdrawal threshold of
the vehicle-treated group (𝑛 = 7), buprenorphine-treated group
(𝑛 = 8), and ketorolac-treated group (𝑛 = 8). Vehicle treatment
group was significantly decreased by the end of postsurgery day
1 through day 21. Treatment groups comparison demonstrated
that the buprenorphine group exhibited paw withdrawal thresholds
significantly lower than vehicle-treated groups from postsurgery
day 1 through day 14 (∗𝑝 < 0.001). Ketorolac treatment induces
a significant difference in PWT when compared to vehicle-treated
animals from postsurgery day 3 through day 21 (#𝑝 < 0.001). Error
bars represent SEM.
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from presurgical baseline levels. However, vehicle-group-
versus-treatment-group differences were limited to only the
buprenorphine-treated animals on day 1.Thebuprenorphine-
treated animals were significantly lower than the vehicle-
treated animal responses (buprenorphine, 24 ± 3.77mN
versus vehicle, 56.5 ± 3.5; repeated measures ANOVA F
= 24.54, 𝑝 < 0.0001). Statistically significant differences
between buprenorphine and vehicle-treated animals groups
continued through day 14. The NSAID-treated group did
not differ from vehicle-treated animals until day 4. On day
4, NSAID-treated animals exhibited a PWT of 51.5 ± 4.67
which was significantly higher than vehicle-treated PWT of
36.5 ± 4.5 (repeated measures ANOVA F = 23.99, 𝑝 <
0.0001). Statistically significant differences between NSAID-
and vehicle-treated animals groups continued through day 21.
4. Discussion
Ketorolac and buprenorphine were studied in rodents sub-
jected to abdominal placement of biotelemetry blood pres-
sure/activity transmitters in an effort to identify which drug
treatment provided better control of postsurgical physio-
logical changes, corticosterone levels, and pain behavior in
rodents when compared to vehicle. With the exception of a
transient change in MAP four days after surgical procedure
in the animals subjected to buprenorphine, biotelemetry
changes were not altered in the rodents. Fecal corticosterone
levels were elevated for saline and ketorolac treatments dur-
ing the first 24 hours but returned to baseline for the remain-
der of the study. In contrast, buprenorphine-treated animals
exhibited elevated corticosterone levels for six days when
compared with saline or ketorolac treatments. Moreover,
behavioral analysis of the treatment conditions revealed that
postsurgical buprenorphine treatment significantly enhanced
the display of tactile hyperalgesia from day 1 to day 21 when
compared with the ketorolac-treated group.
Ketorolac is a frequently used nonsteroidal anti-
inflammatory drug to treat postoperative pain. The
mechanistic actions of ketorolac include inhibiting the
bodily synthesis of prostaglandins including prostaglandin
E2 (PGE2).The nonselective inhibitory effects of ketorolac on
cyclooxygenase products associated with PGE2 production
due to tissue damage likely provide much of the peripheral
analgesia observed with exposure to the drug treatment
[23]. The degree to which the drug contributes to central
nervous system effects is unknown though biodisposition of
ketorolac within the central nervous system may contribute
to greater behavioral efficacy for tactile allodynia as opposed
to modulation of thermal nociception [24, 25]. Despite
the apparent advantages of both selective and nonselective
COX inhibitor to provide analgesia in perioperative settings,
long-term use of these drugs is limited due to a number
of off-target effects including effects on the cardiovascular
system, gastrointestinal erosions, and renal and hepatic
insufficiency [26].
Opioid drugs, such as buprenorphine, are important
components ofmany surgical anesthesia regimens andwidely
believed to be the most potent available postprocedural
analgesics. Buprenorphine is often used as it is longer-acting
and is good formost postoperative applications.The duration
of action is thought to be 6–12 hours; however it is closer
to 6 hours in most situations. As noted in Methods, the
recommended dose of buprenorphine utilized by the NIH
Office of Animal Care and Use (OACU) for rat laparotomy
is 0.01–0.05mg/kg SC or IP. However, as this laparotomy
procedure produces a permanent occlusion of the abdominal
aorta, we opted to use the 0.06mg/kg in these studies [27].
Despite the increased dose, buprenorphine was less effective
than ketorolac in our behavioral studies. Other groups
have noted that this commonly accepted “gold standard”
opioid was also not effective for postoperative analgesia in
male or female Long-Evans or Sprague-Dawley rats [28–
30]. One interpretation of the observed enhancement of
pain-like behavior in the buprenorphine-treated animals
for up to three weeks after the surgical procedure may be
due to a buprenorphine-induced change in the behavioral
state [31]. To this end, there are a growing number of
publications that provide evidence that opiate analgesics
(e.g.,morphine, fentanyl, hydroxymorphine,methadone, and
perhaps buprenorphine), in addition to their antinocicep-
tive properties, can also activate a pain facilitatory system
that effectively enhances pain-like behavior in preclinical
conditions [32–37] and pain sensitivity in clinical situations
[38–40]. This condition is commonly referred to as opiate-
induced hyperalgesia (OIH).
The molecular mechanisms of OIH are largely unknown
although OIH appears to share characteristics of neuropathic
pain and consequently has important clinical implications
and can be defined as an increasing sensitivity to noxious
stimuli, even evolving a painful response to previously non-
noxious stimuli. Some groups have suggested that OIH may
be due to tonic, descending facilitation in the dorsal horn
of the spinal cord through changes in activity of NMDA
receptors [41]. Although neither of these modes of action can
be completely ruled out, the clinical OIH mechanism may
also depend on opioid-induced activation of neuronal Toll-
like receptor 4 (TLR4) [42]. Recent preclinical evidence sug-
gests that opioid activation of TLR4 present on nociceptive
primary sensory neurons cells serves to increase the voltage
gated sodium channel (VGSC-NaV1.7; SCN9A in humans)
current density which contributes directly to the diminished
efficacy of opioids in chronic pain management [36, 43].
Corticosterone levels were monitored using fecal cor-
ticosterone samples. Plasma corticosterone has previously
been the preferred method for monitoring corticosterone.
However, fecal corticosterone measurements allow for a
noninvasive means to monitor corticosterone levels and
can detect up to 80 percent of systemically administered
radioactive corticosterone [18, 19]. The greatest advantage to
utilization of fecal samples is the lack of handling or restraint
required, which have been shown to produce increases in
circulating corticosterone levels [20–22, 44].
The observed prolonged increase in fecal corticosterone
levels following buprenorphine injections represents an inter-
esting insight into the state of these animals after surgery.
Although the animals across the treatment groups exhibited
similar activity levels the corticosterone levels were elevated
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only in the buprenorphine treatment group. Glucocorticoids
such as corticosterone are known as stress hormones whose
regulation is controlled by the HPA axis. Stimulation of the
HPA axis through such effectors as stress or injury can lead
to increased circulating levels [12, 17]. Additionally, these
enhanced circulating levels have been shown to contribute to
nociceptive behavior, which can be reversed by the glucocor-
ticoid receptor antagonist, RU486 [22]. Furthermore, opioid
treatment previously has been shown to increase circulating
corticosterone levels in a number of studies through activat-
ing the HPA [45–47], whereas the use of NSAIDs does not
lead to an increase in corticosterone levels [48, 49].
The presence of tactile hyperalgesic behavior following
surgical procedures is not a novel finding in postsurgical con-
ditions [23]. However, given that placement of the telemetry
device and the resultant occlusion of the abdominal aorta
permanently impact vascular perfusion of the lumbosacral
spinal cord as well as the ancillary sensory ganglion and affil-
iated peripheral nerves the production of prostaglandins and
proinflammatory cytokines and chemokines in the periphery
may contribute to the maintenance of this type of tactile
hyperalgesia beyond the testing period [50].
In summary, our results show that ketorolac is superior
to buprenorphine in rats recovering from abdominal surgery.
Buprenorphine enhanced the tactile hyperalgesic behavior
following surgery and was associated with increased fecal
corticosterone levels.These data indicate that standard opioid
treatment of postsurgical pain may not lead to the best
outcomes in rodents subjected to major survival surgical
procedures.
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